SION (Sionna Therapeutics) Long-Term Debt: $0.00 Mil (As of Mar. 2026)


SION Sionna Therapeutics Inc SION
12 GF Score
Price $43.99
! 3 Warning Signs
View Full Analysis

What is Sionna Therapeutics Long-Term Debt?

Sionna Therapeutics SION +5.64% 12 Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates SION with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Sionna Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Sionna Therapeutics  (NAS:SION) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Sionna Therapeutics Long-Term Debt Related Terms

Sionna Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Sionna Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sionna Therapeutics Long-Term Debt Chart

Sionna Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Long-Term Debt
0.00 0.00 0.00 0.00

Sionna Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SION
12GF Score
Sionna Therapeutics Inc SION
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Sionna Therapeutics (SION) has a Long-Term Debt of $0.00 Mil as of Mar. 2026.
Is Sionna Therapeutics' Long-Term Debt too high?
Sionna Therapeutics' current Long-Term Debt is $0.00 Mil. Overall, Sionna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sionna Therapeutics' Long-Term Debt compare to TYRA and RAPP?
Sionna Therapeutics' Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Sionna Therapeutics's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sionna Therapeutics stock overvalued right now?
Sionna Therapeutics (SION) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. Sionna Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Sionna Therapeutics (SION), the current Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sionna Therapeutics Business Description

Address 21 Hickory Drive, Suite 500, Waltham, MA, USA, 02451
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
12GF Score

Get the complete analysis for SION

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.99
Price